OP
TGTX icon

ORG Partners’s TG Therapeutics TGTX Stock Holding History

ORG Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-50
Closed -$907 – 1361
2024
Q2 		$907 Buy
+50
New +$798 ﹤0.01% 1575
2023
Q4 		– Sell
-50
Closed -$418 – 1340
2023
Q3 		$418 Hold
50
– – ﹤0.01% 1231
2023
Q2 		$1K Buy
+50
New +$1.29K ﹤0.01% 1240

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ORG Partners's TGTX Position: Q3 2024 in Review

ORG Partners sold out of TG Therapeutics (TGTX) in Q3 2024, closing a stake of 50 shares — an estimated $907 sold.

ORG Partners first reported a position in TGTX in Q2 2023 and held it in 3 quarters. The position peaked at $1K in Q2 2023. 308 funds tracked by Wall St. Rank hold TGTX as of Q3 2024.

  • ORG Partners reported no remaining TG Therapeutics position as of Q3 2024 after selling out during the quarter.
  • ORG Partners sold 50 TG Therapeutics shares in Q3 2024, an estimated $907.
  • ORG Partners first reported a position in TG Therapeutics in Q2 2023 and held it in 3 quarters.
  • ORG Partners's TG Therapeutics position peaked at $1K in Q2 2023.
  • 308 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2024.

Based on ORG Partners's 13F filing for Q3 2024, filed 11 Oct 2024.